PharmaTimes - March 2024

Land of the giants

The genie is out of the bottle, folks – and we can’t put it back in.

When Elon Musk’s people literally implanted a ‘brain-reading’ device into the brain of a human subject, it figuratively implanted another idea into the collective consciousness of humankind.

This is the concept of a futuristic healthcare ecosystem that goes beyond nationalism and governance and into private enterprise or ultra-ambitious selfcare. And, let’s face it, who would not be seduced by big tech’s intervention, especially if it meant the ‘next day delivery’ of appointments, surgery or access to life-transforming medicines.

The sparks of revolution have been triggered by the perfect storm – the promise of digital innovation, the spectre of AI and the reality that the crumbling NHS monolith is currently surviving on the fumes of sentimentality.

In no other walk of life would we stay loyal to a service that won’t engage with you for fve weeks (I could be dead in four!). But that is changing – young people do not so readily celebrate something that they have always known to be one-star terrible, while the broader population is moving towards a system that has fexible functionality.

We are at the precipice of a seismic change in which the true potential of pharma and healthcare professionals can be released, from the ailing hands of a once-great giant into the infnite virtual palms of several others. The handover will happen, but it can’t without our participation – our control.

March 2024 - magazine highlights

Staying AI-head of the game!

Don’t downplay generative AI’s promise for drug discovery

The eliminator

Evidence use for product withdrawal is leaning toward obse...

Exoso-what?

Working out exosomes and optimising the delivery of innova...

Live long and prosper?

Boldly going to Medlab in search of the fabled tricorder

Back to pharma’s future

Start the car – what lies ahead over the next ten years an...

Change is coming

Linking the climate-health nexus and collective responsibi...

Passion project

Rippon Ubhi is the new Country Lead for Sanofi UK and Irel...

Eclectic mix

Diversity in clinical trials – not just ‘nice to have’ but...